PanGen Biotech Announces FY2025 Results, Revenue of KRW 13.42 Billion, Operating Profit at 1.51 Billion

Revenue declined 8.5% YoY, Operating profit grew 47.6% YoY

Sustained growth momentum for EPO, expansion of CDMO business

PanGen Biotech Inc. (CEO Jaeseung Yoon) of Huons Group today posted its financial results for the fiscal year 2025. For the full year, the company reported KRW 13.42 billion in annual separate revenue and KRW 1.51 billion in operating profit. Revenue fell 8.5% year-on-year (YoY), while operating profit rose 47.6%.

Among all business segments, Erythropoietin (EPO) biosimilar for anemia treatment showed strong growth due to expansion in export countries, recording KRW 7.5 billion, representing a YoY increase of 33%.

Overseas sales have increased in Association of Southeast Asian Nations (ASEAN), such as Malaysia, Philippines and Thailand, and full-scale exports have started to Saudi Arabia and Turkiye. PanGen Biotech expects sustained revenue growth, driven by the expansion of its export markets into the Middle East, South America, and Africa.

PanGen Biotech is expanding its biopharmaceutical CDMO services based on good manufacturing practice (GMP) compliant facilities and core technologies. The company’s core advantage lies in PANGEN CHO-TECH, a protein expression technology specialized for CHO cells, the animal cells used for biopharmaceutical production.

PanGen Biotech holds a total of 41 biopharmaceutical production cell lines, including 28 cell lines for therapeutic proteins and 13 cell lines for biosimilar antibodies.

PanGen Biotech has leveraged this platform to secure multiple technology transfer agreements and generate royalty income. Additionally, the company expects a virtuous cycle of revenue as development stages advance and the product portfolio expands.

PanGen Biotech is developing biosimilars for blockbuster drugs currently sold by multinational pharmaceutical companies based on its proprietary CHO-TECH technology.

These are Bristol Myers Squibb (BMS)’s immunotherapy drug Yervoy (ipilimumab), Johnson & Johnson’s autoimmune treatment Tremfya (guselkumab) and Amgen’s osteoporosis treatment Evenity (romosozumab).

Pangen Biotech is already in the process of developing the production cell lines for these 3 products and plans to establish the production process within the year. PanGen Biotech will expand its CDMO business, leveraging its proprietary CHO-cell technologies to develop customized biosimilars for biopharmaceutical companies.

CEO of PanGen Biotech, Dr. Jaeseung Yoon said, "We will continue to drive performance growth by developing biosimilars based on our core CHO cell line development technology. We will strengthen our collaboration within Huons Group and accelerate our strategy to penetrate the global biopharmaceutical market.”